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Abstract
The establishment of cartilage regenerative medicine is an important clinical issue, but the search for cell 
sources able to restore cartilage integrity proves to be challenging. Human mesenchymal stromal cells (MSCs) 
are prone to form epiphyseal or hypertrophic cartilage and have an age-related limited proliferation. On 
the other hand, it is difficult to obtain functional chondrocytes from human embryonic stem cells (ESCs). 
Moreover, the ethical issues associated with human ESCs are an additional disadvantage of using such cells.
 Since their discovery in 2006, induced pluripotent stems cells (iPSCs) have opened many gateways to 
regenerative medicine research, especially in cartilage tissue engineering therapies. iPSCs have the capacity 
to overcome limitations associated with current cell sources since large numbers of autologous cells can be 
derived from small starting populations. Moreover, problems associated with epiphyseal or hypertrophic-
cartilage formation can be overcome using iPSCs.
 iPSCs emerge as a promising cell source for treating cartilage defects and have the potential to be used 
in the clinical field. For this purpose, robust protocols to induce chondrogenesis, both in vitro an in vivo, are 
required. This review summarises the recent progress in iPSC technology and its applications for cartilage 
repair.
Keywords: Induced pluripotent stem cells, pluripotency, cartilage, osteoarthritis, cell therapy, tissue 
engineering, regenerative medicine, chondrogenesis.
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Introduction
The development of a multicellular organism begins 
from a single-cell, the zygote, which divides in a quick 
and regulated manner during gestation. The cells 
from the first two divisions, namely the totipotent 
cells, are able to generate both embryonic and extra 
embryonic tissues (placenta). As these cells divide, 
their potency to generate extra embryonic tissues 
is lost and they become pluripotent cells, which are 
able to differentiate into cells that arise from the three 
germ layers: endoderm, mesoderm and ectoderm 
(Evans and Kaufman, 1981).
 Although embryonic stem cells (ESCs), derived 
from the inner cell mass of the blastocyst (Evans and 
Kaufman, 1981; Thomson et al., 1998), and the cells in 
the germinal ridge of the embryo (Nichols and Smith, 
2007) were thought to be the only type of pluripotent 
cells known, Takahasi and Yamanaka (2006) show 
that it is possible to activate a class of genes within 
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adult cells that cause a reversion to a pluripotent 
state. Using retroviruses to deliver and force the 
expression of four transcriptional factors [octamer-
binding transcription factor 4 (Oct4), sex determining 
region Y-box 2 (Sox2), c-Myc and Kruppel-like factor 
4 (Klf4)], mouse tail-tip fibroblasts are reprogrammed 
into cells similar to ESCs, called induced pluripotent 
stem cells (iPSCs) (Takahashi and Yamanaka, 2006). 
The same protocol can successfully reprogram 
human fibroblasts (Takahashi et al., 2007). The 
generation of iPSCs is now achieved from a variety 
of species (Harding and Mirochnitchenko, 2014) 
and a wide range of somatic cell types (Web ref. 1; 
Web ref. 2). Although the reprogramming efficiency 
varies among somatic cell types, accessible and 
abundant differentiated cell types, such as fibroblasts, 
keratinocytes or blood cells, can be directed into a 
pluripotent cell state (Brouwer et al., 2016; Driessen 
et al., 2017; Higgins et al., 2012).
 iPSCs and ESCs share the properties of unlimited 
self-renewal and pluripotency (Narsinh et al., 
2011). Also, they are similar in terms of surface 
marker expression, morphology, proliferation, 
gene expression profiles, in vivo teratoma formation 
capacity and telomerase activity (Hirschi et al., 2014; 
Narsinh et al., 2011; Zhao et al., 2013a). However, 
human iPSCs have several advantages over the use 
of human ESCs. iPSCs represent an easily-accessible 
source of patient-specific pluripotent cells and, 
despite the possibility of an immunological response 
and rejection of iPSCs by a recipient patient cannot 
be completely precluded, they are expected to reduce 
the immune response when transplanted (Zhao et al., 
2013a). Also somatic cell nuclear transfer (SCNT) can 
be used to create patient-specific ESCs (Tachibana 
et al., 2013). However, the widespread application 
of SCNT to human cells is challenging due to the 
need for mature, developmentally competent human 
oocytes, which leads to issues regarding the use of 
human oocytes for research. In this sense, iPSCs can 
bypass the ethical and political issues related to the 
use of human ESCs because the destruction of human 
embryos is not needed (Hirschi et al., 2014).
 iPSCs are considered to be a promising tool for 
disease modelling, drug discovery and regenerative 
medicine applications (Hirschi et al., 2014; Lian et 
al., 2010; Okano and Yamanaka, 2014; Rony et al., 
2015; Sayed et al., 2016; Singh et al., 2015; Zhao et 
al., 2013a). In fact, the iPSC technology is already 
implemented to investigate tissue dysfunction at the 
cell and molecular level and to treat both genetic and 
non-genetic diseases (Zhao et al., 2013a).
 Functional cartilage is spontaneously produced 
from human iPSCs in teratomas (Kumazaki et 
al., 2014; Takahashi et al., 2007b; Yu et al., 2007), 
making these cells possible candidates for cartilage 
regenerative medicine applications and a tool for 
studying disease mechanisms and new treatments.
 The aim of this review was to discuss the role of 
iPSCs over recent years in drug discovery, disease 
modelling and regenerative medicine applications. 
Specifically, the focus was on differentiation 
protocols, treatment strategies and results obtained 
in the field of cartilage therapy.
Chondrogenic differentiation of iPSCs
To employ the iPSC technology for cartilage damage 
treatment, drug discovery and disease modelling 
applications, a robust in vitro chondrogenesis is 
required (Augustyniak et al., 2015). To evaluate the 
different methodologies suggested, it is important to 
understand the normal developmental pathways that 
lead to the production of chondrocytes.
 Chondrocyte differentiation is regulated by 
multiple signal transduction pathways, which 
regulate a complex series of events, including 
condensation of mesenchymal progenitor cells 
and nodule formation followed by chondrogenic 
differentiation (Li and Dong, 2016). Several critical 
signalling molecules regulate this process, including 
soluble factors, such as bone morphogenetic proteins 
(BMPs), fibroblast growth factors (FGFs), transforming 
growth factor beta (TGFb), Wnt and cell adhesion 
molecules (N-CAM, N-cadherin, b-catenin) (Matta 
et al., 2014). These factors activate essential targets 
for initiation and maintenance of the chondrocyte 
phenotype. Cartilage-specific transcription factors, 
such as SRY-related high-mobility group-box 
gene 9 (Sox9), are also required for the initial 
condensation of mesenchymal progenitor cells 
and for the maintenance of the chondroprogenitor 
phenotype; therefore, Sox9 is highly expressed during 
chondrogenesis (Li and Dong, 2016). Apart from these 
factors, macromolecules of the cartilage extracellular 
matrix, such as type II collagen, hyaluronan, aggrecan 
or fibronectin, can also act as signalling molecules 
(Matta et al., 2014).
 To assess the effectiveness of chondrogenic 
differentiation, it is important to know to what extent 
the differentiated cells share a similar phenotype 
and genotype with their native counterparts. Since 
no chondrogenic cell surface markers are known, 
chondrogenic differentiation is usually evaluated 
by measuring histological and molecular markers, 
rather than flow cytometry markers (Driessen et al., 
2017). The chondrogenic phenotype is characterised 
by the expression of type II collagen, Sox9, aggrecan 
and high levels of proteoglycans (Dehene et al., 2009; 
Nejadnik et al., 2015). Furthermore, both epiphyseal 
and fibroblastic markers, such as the fibrocartilage 
marker type I collagen and the hypertrophic cartilage 
type X collagen, should be assessed to robustly study 
cells functionality (Dehene et al., 2009; Nejadnik et al., 
2015). Run-related transcription factor 2 (RUNX2), 
matrix metalloproteinase-13 (MMP13) and vascular 
endothelial growth factor (VEGF) are also used as 
markers of epiphyseal phenotype, due to their role in 
the formation of hypertrophic chondrocytes during 
skeletal development (Augustyniak et al., 2015).
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Table 1. Human iPSC chondrogenic differentiation protocols and quality of the chondrogenesis 
obtained. Quality of chondrogenesis is classified according to: expression of positive markers and 
absence of hypertrophic/fibrocartilage markers (good); expression of both positive and negative markers 
(intermediate); lower expression of positive markers than in control (low); if expression of negative 
markers is not studied, the quality of differentiation obtained is not evaluated in the table. Abbreviations: 
EBs (embryo bodies), MSC (mesenchymal stromal cell), COLII (type II collagen), ACAN (aggrecan), 






Assessment of the differentiation
Quality of 
differentiation
Positive markers Negative markers
COLII Sox9 ACAN Others COLI COLX Others
Wei et al., 2012 Co-culture + + GAGs (+) VEGF (−) Good
Qu et al., 2013 Co-culture + + + Intermediate
Medvedev et al., 
2011 EBs formation + + + GAGs (+) + Intermediate
Umeda et al., 
2012 EBs formation + GAGs (+) − Good
Craft et al., 2015 EBs formation + + + − − RUNX2 (−) Good
Lee et al., 2015 EBs formation + + + Sox5 (+)Sox6 (+) − − Good
Liu et al., 2012 MSC-like population + + + GAGs (+) NE
Villa−Diaz et al., 
2012 MSC-like population + + GAGs (+) NE
Koyama et al., 
2013 MSC-like population +/− + +/− GAGs (+) − Intermediate
Zou et al., 2013 MSC-like population GAGs (+) NE
Nejadnik et al., 
2015 MSC-like population + + + + + Low
Chijimatsu et 
al., 2017 MSC-like population + + + GAGs (+) + Intermediate
Borestrom et al., 
2014 Growth factors + + + GAGs (+) − Good
Cheng et al., 
2014 Growth factors + + GAGs (+) NE
Saito et al., 2015 Growth factors + + + Sox6 (+)GAGs (+) NE
Yamashita et al., 
2015 Growth factors + GAGs (+) − − OCN (−) Good
Strategies for chondrogenic differentiation of 
iPSCs in vitro
Knowledge of iPSC chondrogenesis is still in its 
infancy and, therefore, standardisation is lacking, 
leading to many different methodologies showing 
variable results. Very few iPSC studies reach the 
standards of a high quality chondrogenesis, with 
rounded cells embedded individually in extracellular 
matrix rich in type II collagen and proteoglycans 
(Archer and Francis-West, 2003). To offer a wide 
vision of the field, this section summarises the 
different methodologies developed over recent years 
and classifies the protocols according to the quality of 
the chondrogenesis obtained (summarised in Table 1).
 Protocols to differentiate iPSCs chondrogenically 
are grouped in three or four categories (Tsumaki et 
al., 2015): (1) co-culture with primary chondrocytes, 
(2) through embryoid body (EB) formation and (3) 
using combinations of growth factors. All these 
methods are believed to transition through an 
mesenchymal stromal cell (MSC)-like state, but some 
authors perform a more specific procedure to obtain 
an intermediate population of MSC-like cells, thus 
establishing a fourth category: (4) induction of MSC-
like cells. Furthermore, new approaches are reported 
recently, such as the use of conditioned medium 
obtained from human cartilage chondrocytes 
(Suchorska et al., 2017).
Co-culture with primary chondrocytes
The primary advantage of co-culture is that the 
paracrine factors secreted from the chondrocytes 
may stimulate the differentiation of iPSCs into 
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 Lee et al. (2015) report a factor-based protocol 
for differentiating human iPSCs into chondrocytes, 
also through EB formation. Sprouted cells obtained 
after two weeks of differentiation are seeded as a 
3D pellet and cultured in chondrogenic medium 
supplemented with growth factors, as previously 
described (Oldershaw et al., 2010). As a novelty, 
p160-Rho-associated coil kinase (ROCK) inhibitor 
Y27632 is added, which promotes pluripotent 
stem cells survival and enhances Sox9 expression. 
Immunohistochemical stainings and molecular 
analysis reveal good-quality chondrogenesis in the 
3D pellets (Lee et al., 2015).
 Medvedev and colleagues (2011) culture EBs in 
chondrogenic medium supplemented with TGFb3 
and BMP2. After EB dissociation, chondrogenic cells 
can self-assemble dense cartilage-like aggregates in 
vitro, with glycosaminoglycans, Sox9 and aggrecan 
detected (Medvedev et al., 2011). By using this 
protocol, good cell functionality is obtained, but  the 
evaluation of fibrocartilage and hypertrophic markers 
within the aggregates would have been desirable.
Intermediate MSC cellular differentiation
Since MSCs are able to differentiate into the 
chondrogenic, osteogenic and adipogenic lineages 
(Dominici et al., 2006; Sanjurjo-Rodriguez et al., 2016) 
and mesenchymal condensation is a prerequisite for 
chondrogenesis induction during embryonic cartilage 
formation (Lietman, 2016), another differentiation 
strategy is to first stimulate iPSC differentiation 
into a MSC-like population, followed by their 
differentiation towards chondrocytes. To establish 
MSC-like populations from iPSCs, several strategies 
are investigated, including the use of coatings (Liu et 
al., 2012), growth factors (Nejadnik et al., 2015) and EB 
formation (Koyama et al., 2013; Villa-Diaz et al., 2012).
 Differentiation of iPSCs into MSCs by forming EBs 
is performed by Koyama et al. (2013) and Villa-Diaz 
et al. (2012). These protocols involve EB formation, 
monolayer culture of sprouted cells from EBs into 
MSC medium and 3D pellet culture in chondrogenic 
medium supplemented with i) dexamethasone and 
TGFb3 or ii) ascorbic acid, dexamethasone and TGFb3. 
Comparison with human native chondrocytes is only 
performed in Koyama’s protocol, revealing that 
human iPSCs differentiate into pre-chondrogenic-
like cells but are not equivalent to fully mature 
chondrocytes.
 Zou et al. (2013) establish a method for deriving 
MSCs from human iPSCs avoiding the EB formation, 
culturing the iPSCs directly in MSC differentiation 
medium followed by serial trypsinisation-based 
passaging. For chondrogenic differentiation, pellets 
are formed, which are cultured in chondrogenic 
medium supplemented with TGFb3. Similarly, 
Nejadnik and colleagues (2015) report another 
approach involving direct induction of human MSCs 
under specific cell culture conditions, followed by 
chondrogenic differentiation with TGFb3. Cells 
at day 14 of chondrogenic differentiation present 
chondrocytes by mimicking the in vivo environment 
found in the tissue (Tsumaki et al., 2015; Wei et al., 
2012). By contrast, the co-culture conditions may 
increase the risk of contamination of differentiated 
cells with other undesired cells (Lietman, 2016). 
This strategy is followed by Wei et al. (2012): to 
promote chondrogenic differentiation, lentiviruses 
are used to transduce human iPSCs with TGFb type 1 
(TGFb1); next, the iPSCs are co-cultured in vitro with 
human healthy chondrocytes. After differentiation, 
proteoglycans presence is detected inside the matrix, 
the expression levels of type II collagen and aggrecan 
are similar to that of human chondrocytes and the 
presence of the VEGF is not detected (Wei et al., 2012). 
Qu et al. (2013) co-culture iPSCs in a trans-well system 
along with bovine articular chondrocytes. Then, 
differentiated cells are expanded and pellet culture is 
performed in chondrogenic medium supplemented 
with TGFb3. Using this protocol, an incomplete 
chondrogenesis is obtained. The iPSC-derived 
chondrocytes show similar expression levels of type 
II collagen and Sox9 to the bovine chondrocytes, 
but they also present higher levels of type I collagen 
(Qu et al., 2013). Adding soluble molecules such as 
BMP or other members of the TGFb family to the 
culture medium could improve the quality of the 
differentiation.
Embryoid bodies formation
In vitro chondrogenic differentiation of iPSCs 
through EB formation is the most common approach 
for obtaining human iPSC-derived chondrocytes 
(Suchorska et al., 2017). Their three-dimensional (3D) 
structure is considered to be similar to that in the early 
post-implantation embryo and, therefore, the cells in 
the EB should be able to differentiate into cells from 
the three germ layers (Cheng et al., 2014).
 Several groups employ this strategy with certain 
success. Craft et al. (2015) reach a high-quality 
chondrogenesis by culturing human iPSC-derived 
EBs in the presence of mesoderm-specific transcription 
factors. After this first differentiation step, the EB is 
dissociated, the cells are sorted according to primitive 
streak/early mesoderm markers and the resultant 
cells are cultured at high density/micromasses in the 
presence of TGFb3. Resultant cells express high levels 
of type II collagen, Sox9 and aggrecan in comparison 
with both healthy chondrocytes and hypertrophic 
chondrocytes; no presence of type I collagen, type X 
collagen or RUNX2 is detected (Craft et al., 2015).
 Umeda et al. (2012) differentiate iPSCs to paraxial 
mesoderm using EB culture, using specific time and 
dose-combination of growth factors and cell sorting 
techniques, both with EB cells and EB-outgrowth 
cells. To stimulate chondrogenic differentiation, 
platelet-derived growth factor (PDGF), TGFb3 and 
BMP4 are used. Although most of the differentiated 
cells are ESCs, also iPSC-derived cells showing 
robust chondrogenesis and generating hyaline-like 
cartilaginous particles are obtained (Umeda et al., 
2012).
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significantly increased gene expression of the hyaline 
chondrogenic markers, compared to human iPSCs-
MSCs before differentiation. However, an increased 
expression of type I and type X collagen is also shown 
(Nejadnik et al., 2015). Chijimatsu et al. (2017) generate 
MSC-like cells from iPSCs by using specific culture 
media, which are subjected to 3D pellet culture system 
using TGFb3 and BMP2. Molecular and histological 
evaluation of chondrogenic differentiation show 
that pellets undergo chondrogenesis. However, cells 
exhibit features of hypertrophic chondrogenesis 
with type X collagen upregulation, suggesting that 
incomplete chondrogenesis is obtained (Chijimatsu 
et al., 2017).
 Another strategy for generating MSCs from iPSCs 
is based on the use of coatings during cell culture 
(Liu et al., 2012). Besides being an osteogenic and 
chondrogenic differentiation promoter of MSCs, type 
I collagen stimulates the epithelial-to-mesenchymal 
transition (Medici and Nawshad, 2010) and, thus, it 
is used for the generation of MSCs from pluripotent 
stem cells. For example, Liu et al. (2012) report a one-
step method to derive MSC-like cells from human 
iPSCs using fibrillar type-I-collagen-coated plates. 
This method consists in the generation of a thin layer 
of collagen fibrils onto the plates, which successfully 
stimulates the derivation of MSC-like cells, as shown 
by the expression of MSC surface markers. For 
chondrogenic differentiation, the standard protocol 
originally described by Johnstone et al. (1998) is used.
Growth factors
Several studies test the efficacy of administrating 
growth factors, such as BMPs, TGFs, insulin-like 
growth factors and FGFs. Since this approach is 
based on reproducing the events that during the 
embryo development “guide” the differentiation 
process, it is also known as “directed differentiation” 
(Augustyniak et al., 2015; Suchorska et al., 2017). 
Cheng et al. (2014) successfully apply in iPSCs 
the protocol already developed for the direct 
differentiation of human ESCs towards chondrocytes. 
This protocol is based on a sequence of pathways 
activated during development and involves the 
use of different growth factors, such as activin-A, 
Wnt3a, FGF2, BMP4, neurotrophin-4 and the growth 
differentiation factor 5 (GDF5). Chondrogenic cell 
aggregates, expressing Sox9 and positive for safranin 
O staining, are observed at the end of the protocol. 
Also, gene expression of chondrogenic markers is 
higher than in iPSCs before differentiation but no 
evaluation of hypertrophic or fibrocartilaginous 
markers is performed (Cheng et al., 2014). With 
similar results, this protocol is also applied by Saito 
et al. (2015) to differentiate human iPSCs.
 The Yamashita et al. (2015) protocol consists 
in initially differentiating human iPSCs into 
mesendodermal cells, as previously reported 
(Oldershaw et al., 2010; Umeda et al., 2012), and, 
then, culturing them in chondrogenic medium 
supplemented with ascorbic acid, BMP2, TGFb1 
and GDF5. Next, chondrogenically-committed cells 
are sorted according to collagen type II expression 
and cultured in 3D. Following this protocol, 
cartilaginous particles with rounded cells embedded 
in extracellular matrix rich in collagen type II, 
proteoglycans and with no presence of collagen type 
X are obtained.
 A good-quality chondrogenesis is achieved by 
Borestrom et al. (2014). Their protocol involves a 3D 
pellet pre-differentiation stage, followed by monolayer 
expansion of chondrogenic progenitors. These 
progenitors are cultured in a second chondrogenic 
3D pellet and differentiated into chondrocytes using 
chondrogenic medium supplemented with growth 
factors. Gene expression levels of Sox9, type II 
collagen, aggrecan and type X collagen are similar to 
that of human articular chondrocytes. Furthermore, 
intense blue colour is observed inside the 3D pellets 
following alcian blue staining and immunostaining 
for type II collagen results positive.
Achievements and current challenges in iPSC 
chondrogenesis
The protocol by Oldershaw et al. (2010) has an 
enormous impact in the field of stem cells and 
cartilage research. However, its application to iPSCs 
is unsuccessful mainly due to the low cell viability. 
The optimisation of this directed differentiation 
method performed by Umeda et al. (2012) focusses 
on the modulation of Wnt and TGFb signalling and 
it succeeds in overcoming the cell viability problems. 
It also allows the generation of high quality hyaline 
cartilage-like tissue and the identification of key 
molecules to trigger iPSC chondrogenesis, becoming 
one of the highest impact protocols in the field. 
Additionally, achieving homogeneous chondrogenic 
cell populations is another important challenge, 
especially when protocols involving EB formation are 
developed (Lietman, 2016; Liu et al., 2012; Nejadnik 
et al., 2015). The establishment of purification steps 
along the differentiation protocol is a big advance, 
as confirmed by the results achieved by Craft et al. 
(2015) and Yamashita et al. (2015).
 Apart from these achievements, there are still 
many challenges and questions that remain open. 
First, chondrogenic differentiation of iPSCs is 
cost- and time-consuming. Second, the quality of 
the derived chondrocytes is not always evaluated 
in depth and sometimes they show hypertrophic 
or fibrocartilaginous characteristics. Third, it is not 
yet clarified which is the best method for deriving 
chondrocytes from iPSCs. Regarding this last point, 
it is not easy neither to establish a comparison 
between all the methods available nor to determine 
the quality of the chondrogenesis objectively, mainly 
due to the different methodologies presented. 
Moreover, each protocol uses different iPSC lines, 
derived from different somatic cell types by using 
different reprogramming methodologies, which 
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could interfere in the research outcome. Few 
research studies comparing different methodologies 
in a structured way are conducted and even less 
comparing different cell sources or different cell lines. 
Suchorska et al. (2017) try to elucidate some of these 
questions by comparing four methods to stimulate 
chondrogenesis of iPSCs: 1) monolayer culture with 
the addition of growth factors (direct protocol), 
2) EBs in chondrogenic medium with TGFb3, 3) 
EBs in chondrogenic medium with conditioned 
medium from human chondrocytes and 4) EBs in 
chondrogenic medium with conditioned medium 
from human chondrocytes and TGFb3. These 
protocols differentiate iPSCs into cells having similar 
expression levels of chondrogenic markers to human 
chondrocytes. Specifically, the direct protocol or the 
conditioned-medium protocol are the most cost-
effective methods (Suchorska et al., 2017). Similarly, 
Augustyniak and collaborators (2015) compare 
the conditioned protocol and the EB formation 
protocol with TGFb3. Cells differentiated in the 
conditioned medium present characteristic features 
of mature chondrocytes. In contrast, cells cultured 
in the presence of TGFb3 present characteristics of 
hypertrophic chondrocytes (Augustyniak et al., 2015).
 All the methods for obtaining chondrocytes 
from iPSCs have paved the way to develop cartilage 
regenerative medicine therapies. However, it remains 
unclear whether chondrogenically-induced iPSCs can 
be considered to be real human chondrocytes, namely 
cells with the same phenotype and cellular activity as 
the native chondrocytes. Also, it would be important 
to confirm if iPSC chondrogenesis truly matches or 
even improves chondrogenesis of MSCs or healthy 
articular chondrocytes. Disease modelling, drug 
discovery and regenerative medicine applications 
require robust in vitro chondrogenesis and, therefore, 
more research in this field is needed to achieve 
uniform differentiation of the desired cell type and 
to better understand the process of chondrogenesis.
Therapeutic applications of iPSCs
Robust and reproducible protocols to induce iPSC 
chondrogenesis are not yet available; perhaps this is 
the reason why there are so few published studies 
about therapeutic applications of iPSCs in cartilage 
diseases (Lietman, 2016), in comparison with other 
diseases, such as neurodegenerative disorders or 
cardiomyopathies, among others (Lian et al., 2010). 
Nevertheless, with further optimisation of the 
protocols to induce chondroprogenitors and promote 
their chondrogenic differentiation, iPSCs are destined 
to be an attractive cell source for applications in 
drug discovery, disease modelling and regenerative 
therapies, to treat and repair chondral defects.
Disease modelling
Disease modelling consists in the recapitulation of the 
disease of interest in a Petri dish. The idea behind this 
is to derive iPSCs from a patient’s somatic cells and 
differentiate them in vitro into the cell type desired 
(Stadtfeld and Hochedlinger, 2010). Two properties 
of iPSCs are indispensable for this application: 
unlimited self-renewal and differentiation potential 
(Lian et al., 2010; Singh et al., 2015). Since iPSCs 
provide an unlimited source for any desired 
specialised cells, their potential is irrefutable. Hence, 
many studies use patient-specific iPSCs (Das and 
Pal, 2010; Menon et al., 2016; Zhao et al., 2013a). 
Regarding cartilage diseases, most of the studies 
focus on monogenic cartilage-diseases. For example, 
Xu et al. (2016), using an in vitro model of familiar 
osteochondritis dissecans based on the employment 
of iPSCs, reveal that several characteristics of the 
differentiated chondrocytes can help in explaining 
the disease phenotype and susceptibility to cartilage 
injury. Studying chondrocytes differentiated from 
patients’ MSCs and iPSCs, large deregulation and 
aberration in assembled extracellular matrix and 
deregulated cell fate are found, which are caused 
by an abnormal accumulation of mutated aggrecan 
protein. Moreover, the composition of the extracellular 
matrix in patients’ iPSC-derived chondrocytes 
reflects the changes seen in advanced osteoarthritis 
(OA), presenting further evidence of the association 
between familial osteochondritis dissecans and 
early-onset OA (Xu et al., 2016). Patient-derived 
skeletal dysplasia iPSCs are generated by Saitta et 
al. (2014) to study early stages of aberrant cartilage 
formation in vitro. Briefly, the mutation causing the 
dysplasia is found to disrupt the normal sequence 
of differentiation that occurs during endochondral 
bone formation, showing inappropriate expression 
of cartilage markers and abnormal TGFb1 and 
BMP2 signalling (Saitta et al., 2014). Yokoyama et al. 
(2015) study an auto-inflammatory disease, called 
neonatal-onset multisystem inflammatory disease 
(NOMID), which is caused by NACHT, LRR and PYD 
domains-containing protein 3 (NALP3) mutations, 
through the iPSC technology. They establish wild-
type and mutant iPSCs, stimulate them to trigger 
chondrogenic differentiation, both in vivo and in vitro, 
and compare the phenotypes of the chondrocytes 
and the chondrogenic tissue generated. Finally, Sox9 
is found overexpressed via the cAMP/PKA/CREB 
signalling pathway in chondrocytes with disease-
causing mutations in NLRP3, causing extracellular 
matrix overproduction (Yokoyama et al., 2015).
 Besides for examining genetic diseases, patient-
specific iPSCs are also useful for studying complex 
diseases affected by several factors, such as genetic 
background and environmental modifications (Lee 
et al., 2014; Liu et al., 2016). Thus, iPSC modelling 
may be promising for studying OA and other 
polygenic cartilage disorders, as they present a 
complex pathophysiology. In this sense, iPSCs 
are also generated from patients with rheumatoid 
arthritis (Lee et al., 2014) and OA (Kim et al., 2011; 
Lee et al., 2014). On the other hand, multiple single 
nucleotide polymorphisms (SNPs) play different 
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roles in the pathogenesis of OA and its subtypes 
(Wang et al., 2016) and, therefore, it would be of 
great interest to develop a model of OA based on 
the use of these SNPs, for which many susceptibility 
loci are known(Wang et al., 2016). The establishment 
of human iPSC-based models of OA could help 
researchers to identify important molecules and 
events that play a key role in the development and 
progression of OA directly in the susceptible cell 
type. At this point, it is important to find a phenotype 
directly linked to the disease, which would enable 
to model it in vitro. Another important issue is the 
generation of stable chondrocytes/cartilage and 
hypertrophic chondrocytes/cartilage to perform 
comparisons between disease forms. Although these 
concerns are still to be solved, the iPSC potential in 
this field is exciting and all the studies developed 
to date represent a first step towards this goal. 
Findings from modelling diseases may help to better 
understand the disease and ultimately develop a 
treatment (Singh et al., 2015) that could be tested in 
these disease models.
Drug discovery
Before performing human clinical trials, the toxicity 
of any novel drug should be tested in animal 
models, to obtain reliable data about the drug 
effects and side effects (Singh et al., 2015). However, 
these models are limited because animals and 
humans possess significant differences (genetic 
background, anatomy and pathophysiology) and 
animal models are incapable of exactly replicating 
human physiological conditions (Lian et al., 2010; 
Okano and Yamanaka, 2014). Also, some compounds 
may have species-specific toxicity in animals (Singh 
et al., 2015). Focussing specifically on OA, the disease 
progress is slower in humans than in animals and the 
pathological changes of the OA animal model may 
not be entirely consistent with those of the human 
disease (Liu et al., 2016). Thus, additional drug 
screening model systems are needed to better mimic 
human conditions and to evaluate whether the results 
could be extrapolated to humans.
 iPSC culture would represent an alternative to 
developing animal models of the disease. The use 
of iPSCs offers a better alternative to conventional 
pharmacological and toxicological tests, allowing 
the generation of human disease-specific cell types 
to enable better prediction of therapeutic response 
and toxicology (Qi et al., 2014). Additionally, iPSCs 
are a valuable tool for seeking compounds or growth 
factors that can improve current differentiation 
protocols. In this sense, Yang et al. (2012) show a 
screening platform using human iPSCs in a multi-
well plate format to identify compounds that can 
promote chondrogenesis. They generate iPSCs 
from human keratinocytes and establish reporter 
lines that can represent endogenous collagen II 
expression levels based on luciferase activity. Two 
chimeric ligands of activin/BMP2 are tested at two 
different doses and their effects are compared to cells 
treated with GDF5. Higher concentrations of each 
of these two compounds can improve chondrogenic 
differentiation as compared to GDF5 (Yang et al., 
2012). Similarly, Yamashita et al. (2015) generate a 
chondrocyte-specific reporter human iPSC line that 
expresses GFP when differentiated into chondrocytes. 
This line is used to search for the culture conditions 
that drive the differentiation of iPSCs towards 
chondrocytes. For this purpose, the cells are firstly 
differentiated into mesendodermal cells, then, the 
medium is changed to basal medium with three 
different types of supplementation. BMP2, TGFb1 
and GDF5 result to be critical for GFP expression 
and, therefore, for the chondrogenic differentiation 
of iPSCs (Yamashita et al., 2015).
 Some drugs are already tested on iPSC models 
of different diseases (Zhao et al., 2013a). With regard 
to cartilage disorders, Willard et al. (2014) show a 
screening of candidate OA drugs in murine iPSC 
and find that the NF-kB inhibitor SC-514 effectively 
reduces cartilage loss in response to inflammatory 
conditions.
 These studies illustrate that the use of iPSCs as 
a screening platform could pave the way for a more 
precise and personalised medicine, which would 
enable the study of the effect of various novel drugs 
at an individual level (Novak et al., 2014). Combining 
these screening platforms with a library of iPSCs from 
different patients with the same disease may provide 
insight into the genetic and potentially epigenetic 
variation of a population (Lian et al., 2010).
Regenerative medicine and cartilage tissue 
engineering using IPSCs
Articular cartilage has a poor intrinsic capacity 
for repair due to its avascular nature and the poor 
stem or progenitor cells access. Therefore, cartilage 
defects due to traumatic or pathological conditions 
slowly grow over time, eventually leading to more 
complex disorders, such as OA (Diekman et al., 
2012; Oldershaw et al., 2010; Yamashita et al., 2015). 
Currently, there is no cure for OA. Treatments are 
mainly focussed on pain management, slowing 
degradation and reducing inflammation, with total 
joint replacement usually needed in the end phase 
of the disease (Fuentes-Boquete et al., 2007; Willard 
et al., 2014; Zhang et al., 2016). New treatments 
based on regenerative medicine and cartilage tissue 
engineering could offer new solutions to preserve, 
repair and restore the integrity of articular cartilage 
(Fig. 1). By treating small or focal defects in cartilage, 
it could be possible to avoid or reduce damage 
progression and generalised degradation, as seen in 
OA (Fuentes-Boquete et al., 2007.
 iPSCs are widely used in cartilage tissue 
engineering because they allow for the use of 
abundant, accessible and autologous cells for 
cartilage formation, bypassing ethical concerns. In 
contrast, other cell sources as MSCs or chondrocytes 
are difficult to obtain and show changes in their 
phenotype and differentiation potential after several 
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passages (Diekman et al., 2012). For this purpose, 
the application of an appropriate scaffold plays a 
decisive role (Cavallo et al., 2010) and, therefore, many 
studies using scaffolds or gel carriers to enhance 
the chondrogenesis of iPSCs have been performed. 
However, most of the investigations already 
published are carried out using mouse-derived iPSCs 
(Table 2).
 Scaffolds employed in cartilage tissue engineering 
using iPSCs are commonly composed of different 
natural biopolymers or synthetic polymers, ranging 
from agarose hydrogels to polycaprolactone 
scaffolds. Diekman et al. (2012) report the creation 
of tissue-engineered cartilage constructs from 
murine iPSCs by using a starting population of 
prechondrogenic cells embedded in an agarose gel. 
Their potential to be used for repairing cartilage is 
examined using an in vitro defect model system. Cells 
show cartilaginous matrix production and integration 
with the surrounding explant cartilage, as determined 
by histology. In addition, the engineered cartilage has 
similar mechanical properties to the native cartilage 
(Diekman et al., 2012).
 Uto et al. (2013) embed iPSCs within a collagen 
hydrogel and introduce it inside a defect prepared 
at the mice patellar groove. Joints filled with iPSCs 
embedded within the collagen hydrogel reproduce 
the smooth contour of the joint and, most importantly, 
iPSCs remain in the transplanted site after 8 weeks, 
showing that these cells can engraft and persist inside 
the damaged area (Uto et al., 2013). On the other hand, 
tumour formation at the surgical site is observed in 
some of the mice, which may be avoided by in vitro 
differentiation before implantation.
 Gel scaffolds are highly permeable and allow 
for the homogeneous distribution of the cells (Zhao 
et al., 2013b). Also, they are highly biocompatible 
and present low cytotoxicity (Apelgren et al., 2017). 
Despite being relatively easy to implant, their viscous 
properties may complicate the construct handling 
(Apelgren et al., 2017). Therefore, another strategy is 
to mix gel scaffolds with more rigid ones. Liu et al. 
(2014) fabricate polycaprolactone/gelatine scaffolds 
to enhance chondrogenic differentiation of mouse 
iPSCs. Subsequently, they implant the constructs 
into cartilage defects performed in the rabbit knee 
and assess the efficacy of cartilage restoration. They 
observe by scanning electron microscopy that cells 
can attach to the surface of the scaffold and, also, 
some can infiltrate between the fibres. The formed 
tissue shows a large number of chondrocytes and 
upregulated expression of type II collagen and 
aggrecan. Moreover, after three months, the defects 
are almost entirely filled (Liu et al., 2014).
 Studies using human iPSCs show that human 
iPSC-derived chondrocytes can be grown in 3D 
cultures or scaffolds to create cartilage-like tissue 
in vitro and in vivo (Tsumaki et al., 2015), although 
with different results in terms of the quality of 
the cartilage-like tissue obtained. Kim et al. (2011) 
reprogram human synovial cells from OA patients 
and culture them in polycaprolactone polymer 
scaffolds, finding high levels of chondrogenic 
markers, such as type II collagen and Sox9, but also 
the presence of type I and type X collagen. Similarly, 
Wei et al. (2012) improve the quality of the human 
iPSC chondrogenesis by using an alginate matrix. 
Ko et al. (2014) also use an alginate hydrogel to 
Fig. 1. Scheme illustrating the proposed methodology to perform regenerative medicine for articular 
cartilage by generation of iPSCs. 1) OA patient selection. 2) Harvest of skin biopsy and fibroblast 
isolation by the explant culture technique (scale bar: 200 μm). 3) Reprogramming with Oct4, Sox2, Klf4 
and c-Myc. 4) Culture of iPSC colonies (scale bar: 300 μm). 5) Chondrogenic differentiation of iPSCs to 
obtain cartilage-like tissue. 6) Image showing a slice of healthy human articular cartilage stained with 
haematoxylin-eosin (scale bar: 100 μm).
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differentiate human iPSCs chondrogenically. Then, 
they assess the in vitro capacity of these cells for 
cartilage regeneration using an osteochondral rat 
defect model. The new tissue generated reveals a 
good restoration of the articular surface. Nonetheless, 
despite the persistence of implanted iPSCs in situ, 
reduced amount of proteoglycans as compared with 
adjacent normal cartilage is observed (Ko et al., 2014).
 A pioneering approach in cartilage tissue 
engineering is to 3D print combinations of scaffolds 
and cells to generate a cartilage-like tissue. 3D printing 
consists in laying down successive layers of material 
in different shapes, each one printed directly on top 
of the previous one according to a computer program 
(Dodziuk, 2016). The 3D shape of the bio-printed 
constructs can be very precise, which is important for 
the reconstruction of specific structures (Apelgren et 
al., 2017). Thus, this technique allows the distribution 
of different cells and supporting biomaterials in 
different ways to resemble the microarchitecture of 
the tissues. Nguyen et al. (2017) use this approach, 
combining nanofibrillated cellulose composite bioink 
with human iPSCs. They print the mixture of cells and 
ink as six-layer grids into 24-well plates and culture 
Reference Somatic cell type Chondrogenesis
In vitro/ 
In vivo Animal model Animal




EB formation. Pellet culture 
or agarose culture and 3D 
polycaprolactone scaffold.





Micromasses formation, digestion, 
cell sorting and pellet formation. 
Factors added: BMP4 and TGFb3.
In vitro − −
Wei et al., 2012 OA chondrocytes
EB formation. Lentiviral transduction 
of iPSCs with TGFb1 and co-culture 
with chondrocytes in alginate matrix.
Both Subcutaneous implant Mouse
Uto et al., 2013




Micromasses embedded in collagen 
hydrogel. Factors added: TGFb3. Both
Model of joint defect in 
patellar groove Mouse





Three-steps protocol based on 
the addition of growth factors. 
Factors added: activin A, Wnt3a, 
FGF2, BMP4, GDF5, follistatin and 
neurotrophin 4.
In vivo
Osteochondral defect in 
trochlear groove of the 
femur
Rat





EB formation, disaggregation and 
culture in pellets and alginate 
hydrogel. Factors added: TGFb3.
In vivo
Osteochondral defect on 
the patellar groove of 
the femur
Rat
Liu et al., 2014 Mouse iPSCs
EB formation, trypsinisation and 
cells seeded onto polycaprolactone 
scaffolds. Factors added: TGFb1.
In vivo Knee joint defect Rabbit
Lee et al., 2015 Human fibroblasts
Three-steps protocol based on the 
addition of growth factors + EB 
formation. Factors added: Activin A, 
Wnt3a, FGF2, BMP4, GDF5, follistatin 
and neurotrophin 4.
Both Subcutaneous implant Mouse




Three-steps protocol based on the 
addition of growth factors. Factors 
added: Activin A, WNT3A, FGF2, 
BMP4, GDF5, follistatin and neuro-
trophin 4.
In vivo
Full thickness cartilage 





hiPSC line 409B2 
and mouse cell 
line 604B1
Three-steps protocol based on the ad-
dition of growth factors. Three types 









Nguyen et al., 
2017 A2B iPSC line
Micromass formation, digestion, four 
passages in monolayer and second 
micromass formation. Factors added: 
TGFb1 and TGFb3.
3D printing with irradiated chondro-
cytes in nanocellulose and alginate 
bioink.
In vitro
Table 2. Summary of in vitro and in vivo protocols for cartilage regenerative medicine and tissue 
engineering by using iPSCs. Abbreviations: EB (embryo body), TGFb (transforming growth factor beta), 
BMP (bone morphogenetic protein), OA (osteoarthritis), RA (rheumatoid arthritis), ACI (autologous 
chondrocyte implantation), MEF (mouse embryonic fibroblasts). A (ascorbic acid), ABT (ascorbic 
acid + BMP type 2 + TGFb type 1), ABTG (ascorbic acid + BMP type 2 + TGFb type 1 + GDF5), BMCs 
(bone marrow cells).
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them in chondrogenic differentiation medium. iPSCs 
can maintain a pluripotent phenotype after 3D 
bioprinting and cartilage-like tissue expressing type 
II collagen is observed after five weeks of culture 
in chondrogenic medium (Nguyen et al., 2017). 
Although this approach is still in its infancy, this 
research suggests that 3D bioprinting with iPSCs may 
be the future treatment to repair damaged cartilage 
in joints.
Discussion
The remarkable properties of pluripotent stem cells, 
as ESCs and iPSCs, make them promising tools with 
great potential for cell therapy and regenerative 
medicine applications. However, the use of human 
ESCs is linked to ethical barriers, as well as problems 
related to the immune response. Since Takahashi 
and Yamanaka made the landmark discovery of 
reprogramming differentiated cells into a pluripotent 
state in 2006, allowing for the procurement of 
pluripotent cells in a non-invasive manner and 
eluding ethical problems, researchers can work with 
pluripotent cells bypassing the concerns of using 
human ESCs.
 Reproducing different diseases in a Petri dish, 
testing new drugs and compounds in the human 
cells of interest and generating successful tissues 
for implantation and repair is getting more feasible 
thanks to the use of iPSCs. In this sense, numerous 
studies show the potential of iPSCs for treating 
cartilage lesions. Nevertheless, to be able to apply 
iPSC for cartilage repair, efficient protocols to 
differentiate the iPSCs chondrogenically are required. 
Many protocols of chondrogenic differentiation are 
described but all of them using different growth 
factors, varying culture times, intermediate steps 
and different culture systems (monolayer and pellet). 
There is still no general agreement concerning the 
best approach to obtain chondrocytes; for this reason, 
studies systematically comparing the different 
approaches would be helpful. Likewise, it is too soon 
to firmly state that iPSCs are better than MSCs for 
cartilage therapies, but there is no doubt that iPSCs 
can improve several issues, such as accessibility, cell 
number, fibrocartilage formation or phenotype loss 
with passages.
 Monogenic cartilage diseases are more likely to 
be modelled by using iPSCs and recently, the use 
of these cells to model disorders, such as skeletal 
dysplasia, has produced positive results (Liu et al., 
2016). In the field of iPSCs and OA, opportunities and 
challenges coexist. iPSC models can be a valuable tool 
for understanding disease mechanisms and perhaps 
to test potential drugs for clinical use, although it is 
still necessary to find a specific phenotype in vitro. 
According to Liu et al. (2016), the establishment of the 
human iPSC-based models of the OA can accelerate 
the exploration of the pathogenesis of the disease and 
be a significant step towards potential treatments.
 The uses of iPSCs for tissue engineering 
applications are more focussed in the fields of 
cardiology or neurology than rheumatology. 
Studies developed to date using iPSCs with and 
without scaffolds have obtained cartilage-like 
tissue, which is, however, still different from hyaline 
articular cartilage. The important part is that iPSCs 
can engraft and persist inside the lesions and 
produce extracellular matrix when chondrogenic 
differentiation is stimulated. Finally, although the 3D 
printing with iPSCs approach is still in its infancy, 
it has an enormous potential and may be the future 
treatment to repair damaged cartilage in joints.
Conclusion
To continue progressing in this field, it is extremely 
important to reach a consensus about what are 
the minimum requirements for considering that 
chondrogenically differentiated iPSCs fulfil the 
threshold of mature chondrocytes. These criteria 
would likely be (1) obtaining rounded or polygonal 
cells (2) embedded individually in extracellular 
matrix (3) rich in type II collagen and proteoglycans 
and in (4) the absence of epiphyseal markers, such as 
alkaline phosphatase and type X collagen.
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Discussion with Reviewer
Solvig Diederichs: Is in vitro chondrogenesis of iPSCs 
already sufficiently efficient to consider iPS cells an 
attractive alternative to primary chondrocytes and 
MSCs?
Authors: Multiple cell-based approaches attempt to 
restore hyaline cartilage and prevent degeneration 
(Fuentes-Boquete et al., 2007) but formation of 
high-quality cartilage is not yet achieved. The use 
of chondrocytes and MSCs is linked to several 
drawbacks, such as limited availability, loss of 
phenotype in culture, invasive harvesting procedures 
and fibrocartilage or hypertrophic cartilage formation. 
iPSCs represent a promising alternative, mainly 
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due to two properties: unlimited self-renew and 
chondrogenic differentiation potential. However, 
few studies show high-quality cartilage from 
iPSCs(Chiramatsu et al., 2017; Craft et al., 2015; 
Lee et al., 2015; Umeda et al., 2012; Wei et al., 2012). 
Indeed, the availability of many studies applying 
different protocols introduce significant variability 
and create confusion. iPSCs are destined to be a 
very useful source for cartilage therapies and small 
molecule and drug screening applications, since 
they allow the use of abundant, accessible and 
autologous cells bypassing ethical concerns; however, 
iPSC chondrogenesis is not yet efficient enough 
to completely substitute chondrocyte- or MSC-
based therapies. More studies critically comparing 
chondrogenic differentiation between different cell 
types, as MSCs and iPSCs, are needed to elucidate 
this open question.
Solvig Diederichs: Would young cells, such as 
perinatal tissues cells, including cord blood cells, be 
preferable over adult cells that accrue many genetic 
variances during their life time?
Authors: Since the first generation of iPSCs in 
2006, a multitude of somatic cell types have been 
reprogrammed to pluripotency. However, the 
conversion is still highly inefficient (< 1 %) (Maherali 
et al., 2008, additional reference). It is proposed that 
successful generation of iPSCs may be easier to 
achieve from actively dividing cells than from slow/
non-dividing cells (Streckfuss-Boemeke et al., 2013; 
Utikal et al., 2009, additional references), which may 
be explained by a higher capacity of the cells to 
incorporate the reprogramming factors into the host 
genome or to activate the reprogramming signalling 
pathway. Fibroblasts are one of the cell types most 
commonly used for reprogramming because of 
their high proliferation capacity at early passages 
(Streckfuss-Boemeke et al., 2013, additional reference), 
easy cultivation, propagation, cryopreservation 
properties and viability in culture. However, adult 
cells are more likely to accumulate nuclear and 
mitochondrial mutations, which cannot be erased 
during the reprogramming processes and, therefore, 
can interfere in the function and tumour risk of iPSCs 
(Wang et al., 2013, additional reference). In contrast, 
young cells, such as the ones derived from umbilical 
cord blood or placenta, are expected to incorporate 
few somatic mutations when compared to adult 
donor cells (Cai et al., 2010, additional reference). 
Thus, the umbilical cord and placenta emerge as 
promising extra-embryonic tissues for cell therapy 
purposes. Additionally, some studies suggest that 
cells expressing certain degree of multipotency can 
provide a better source for reprogramming (Kato et 
al., 2000, additional reference). In this sense, umbilical 
cord cells express genes found in ESCs, such as Oct4, 
Nanog or Rex-1. Since these cells already express 
several genes required for pluripotency, are readily 
available and are not limited by ethics, they seem to 
be a great cell source to use in reprogramming. The 
advantages and disadvantages of reprogramming 
human cells from different tissues are currently 
unclear but will need careful comparison to find the 
optimal cell source for reprogramming.
 The use of “young cells” is not exempt from 
problems. For example, probably because the 
formation of extra-embryonic tissues occurs very 
early after implantation, extra-embryonic tissue 
cells retain an immature phenotype (Red-Horse et 
al. 2004, additional reference). Thus, an important 
parallel question that emerges is whether modelling 
of late-onset diseases, such as OA could be possible 
when using this kind of “immature cells” for 
reprogramming. This is an important issue that needs 
to be solved for disease modelling, drug screening 
and, eventually, translational applications of iPSCs.
Additional References
 Cai J, Li W, Su H, Qin D, Yang J, Zhu F, Xu J, He 
W, Guo X, Labuda K, Peterbauer A, Wolbanck S, 
Zhong M, Li Z, Wu W, So Kf, Redi H, Zeng L, Esteban 
MA, Pei D (2010) Generation of human induced 
pluripotent stem cells from umbilical cord matrix 
and amniotic membrane mesenchymal cells. J Biol 
Chem 285: 11227-11234.
 Kato Y, Tani T, Tsunada Y (2000) Cloning of claves 
from various somatic cell types of male and female 
adult newborn and fetal cows. J Reprod Fertil 120: 
231-237.
 Maherali N, Ahfeldt T, Rigamonti A, Utikal J, 
Cowan C, Hochedlinger K (2008) A high-efficiency 
system for the generation and study of human 
induced pluripotent stem cells. Cell Stem Cell 3: 340-
345.
 Red-Horse K, Zhou Y, Genbacev O, Prakobphol A, 
Foulk R, Mc-Master M, Fisher SJ (2004) J Clin Invest 
114: 744-754.
 Streckfuss-Boemeke K, Wolf F, Azizian A, Stauske 
M, Tiburcy M, Wagner S, Hübscher D, Dressel R, 
Chen S, Jende J, Wulf G, Lorenz V, Schön MP, Maier 
LS, Zimmermann WH, Hasenfuss G, Guan K (2013) 
Comparative study of human-induced pluripotent 
stem cells derived from bone marrow cells, hair 
keratinocytes, and skin fibroblasts. Eur Heart J 34: 
2618-2629.
 Utikal J, Polo JM, Stadtfeld M, Maherali N, 
Kulalert W, Walsh RM, Khalil A, Rheinwald JG, 
Hochedlinger K (2009) Immortalization eliminates 
a roadblock during cellular reprogramming into iPS 
cells. Nature 460: 1145-1148.
 Wang J, Gu Q, Hao J, Bai D, Liu L, Zhao X, Liu 
Z, Wang L, Zhou Q (2013) Generation of induced 
pluripotent stem cells with high efficiency from 
human umbilical cord blood mononuclear cells. 
Genomics Proteomics Bioinformatics 11: 304-311.
Editor’s note: The Scientific Editor responsible for 
this paper was Martin Stoddart.
